Category: 1029413-55-5

Related Products of 1029413-55-5, In heterogeneous catalysis, the catalyst is in a different phase from the reactants. At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 1029413-55-5, name is tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate. In an article，Which mentioned a new discovery about 1029413-55-5

ALK and ROS1 kinases have become promising therapeutic targets since Crizotinib was used to treat non-small-cell lung cancer clinically. Aiming to explore new potent inhibitors, a series of 2-amino-4-(1-piperidine) pyridine derivatives that stabilized a novel DFG-shifted conformation in the kinase domain of ALK were designed and synthesized on the base of lead compound A. Biological evaluation highlighted that most of these new compounds could also potently inhibit ROS1 kinase, leading to the promising inhibitors against both ROS1 and ALK. Among them, the representative compound 2e stood out potent anti-proliferative activity against ALK-addicted H3122 and ROS1-addicted HCC78 cell lines (IC50 = 6.27 muM and 10.71 muM, respectively), which were comparable to that of Crizotinib. Moreover, 2e showed impressive enzyme activity against clinically Crizotinib-resistant ALKL1196M with an IC50 value of 41.3 nM, which was about 2-fold more potent than that of Crizotinib. 2e also showed potent inhibitory activity in about 6-fold superior to Crizotinib (IC50: 104.7 nM vs. 643.5 nM) in Ba/F3 cell line harboring ROS1G2032R. Furthermore, molecular modeling disclosed that all the representative inhibitors could dock into the active site of ALK and ROS1, which gave a probable explanation of anti Crizotinib-resistant mutants. These results indicated that our work has established a path forward for the generation of anti Crizotinib-resistant ALK/ROS1 dual inhibitors.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.1029413-55-5. In my other articles, you can also check out more blogs about 1029413-55-5

Reference：
Piperidine – Wikipedia,
Piperidine | C5H21625N – PubChem

 

Related Products of 1029413-55-5, Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 1029413-55-5, Name is tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate,introducing its new discovery.

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton’s tyrosine kinase and which exhibit desirable characteristics for the same.

If you’re interested in learning more about 3153-26-2, below is a message from the blog Manager. Related Products of 1029413-55-5

Reference：
Piperidine – Wikipedia,
Piperidine | C5H21608N – PubChem

 

Chemistry is an experimental science, Application In Synthesis of tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate, and the best way to enjoy it and learn about it is performing experiments.Introducing a new discovery about 1029413-55-5, Name is tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate

Triazolopyridine compounds and methods of use (by machine translation)

Provides triazolopyridine compounds, it is JAK kinase, for example JAK1 inhibitors, also provides compositions which contain these compounds and used for the treatment of JAK kinase-mediated disease. In particular, the provision of the formula (I) compound, Its stereoisomer, tautomer, solvate, pro or a pharmaceutically acceptable salt, wherein R1 A , R1 B , R1 C , R2 , R3 , R4 And R5 As defined herein, comprising said compound and a pharmaceutically acceptable carrier, adjuvant or medium of the pharmaceutical composition, in therapy using the compound or composition, such as used for treating the patient by JAK kinase mediated diseases or disorders. (by machine translation)

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Application In Synthesis of tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 1029413-55-5, in my other articles.

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H21612N – PubChem

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬ Computed Properties of C13H22N4O2, Which mentioned a new discovery about 1029413-55-5

PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS

The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1,2,3, or 4, Ackl, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rskl, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, Computed Properties of C13H22N4O2, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 1029413-55-5

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H21599N – PubChem

 

Chemistry is an experimental science, Application In Synthesis of tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate, and the best way to enjoy it and learn about it is performing experiments.Introducing a new discovery about 1029413-55-5, Name is tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate

FLT3 INHIBITORS AND USES THEREOF

The present invention provides methods of using compounds of formula I: or compositions thereof for the inhibition of FLT3, and the treatment of FLT3-mediated disorders.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Application In Synthesis of tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 1029413-55-5, in my other articles.

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H21607N – PubChem

 

1029413-55-5, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 1029413-55-5, molcular formula is C13H22N4O2, introducing its new discovery.

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Enzymes are biological catalysts that produce large increases in reaction rates and tend to be specific for certain reactants and products. I hope my blog about is helpful to your research. 1029413-55-5

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H21615N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1029413-55-5,tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate,as a common compound, the synthetic route is as follows.

Compound 48-b (250 mg, 0.68 mmol) and compound 32-c (181 mg, 0.68 mmol) were dissolved in N,N-dimethylformamide (3 mL), and potassium carbonate (281 mg, 2.37 mmol), 2-dicyclohexylphosphino-2?,6?-diisopropoxy-1,1?-biphenyl (58 mg, 0.13 mmol) and tris(dibenzylideneacetone)dipalladium (136 mg, 0.24 mmol) were added. The reaction solution was heated to 110 C. and stirred for 16 hours under nitrogen gas atmosphere. After cooling to room temperature, the reaction mixture was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel TLC preparative plate (petroleum ether: ethyl acetate=1:1) to give 48-a as a pale yellow solid (75 mg, yield 18%). LC-MS (ESI): m/z=599[M+H]+.

1029413-55-5, As the paragraph descriping shows that 1029413-55-5 is playing an increasingly important role.

Reference£º
Patent; GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.; XU, Zusheng; ZHANG, Nong; WANG, Tinghan; SUN, Qingrui; WANG, Yuguang; (90 pag.)US2018/208604; (2018); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

 

1029413-55-5, tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 2,4-dichioro-i ,3,5-triazine (0.62 g, 4.1 mmol) inN,N-dimethylformamide (DMF, 10 mE) at 0C. were added sequentially N,N-diisopropylethylamine (DIEA, 0.75 mE, 4.3 mmol) and tert-butyl 4-(4-amino-1H-pyrazol–yl)piperidine- 1 -carboxylate (Combi-l3locks, 1.0 g, 3.8 mmol). The mixture was allowed to warm to room temperature. The mixture was diluted with ethyl acetate and water. The aqueous phase basified with saturated aqueous sodium hydrogen carbonate solution and then was extracted thrice with ethyl acetate. The combined extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel) to provide tert-butyl 4-(4-((4- chloro-i ,3,5-triazin-2-yl)amino)- 1H-pyrazol-i -yl)piperidine-i -carboxylate. ECMS-ESI (m/z): [M+H] calcd for C,5H23C1N702: 380.2. found: 379.8

1029413-55-5, As the paragraph descriping shows that 1029413-55-5 is playing an increasingly important role.

Reference£º
Patent; Gilead Sciences, Inc.; Du, Zhimin; Guerrero, Juan A.; Kaplan, Joshua A.; Knox, JR., John E.; Lo, Jennifer R.; Mitchell, Scott A.; Naduthambi, Devan; Phillips, Barton W.; Venkataramani, Chandrasekar; Wang, Peiyuan; Watkins, William J.; Zhao, Zhongdong; (593 pag.)US2016/96827; (2016); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1029413-55-5,tert-Butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate,as a common compound, the synthetic route is as follows.

[0554j A mixture of 2-chloro-4-methoxypyrimidine (970 mg, 6.7 mmol), tert-butyl 4-(4- amino-1H-pyrazol-1-yl)piperidine-1-carboxylate (1.8 g, 6.77 mmol), S-phos (548 mg, 1.35 mmol), Pd2(dba)3 (577 mg, 0.63 mmol) and NaOtBu (1.9 g, 20.2 mmol) in 1,4-dioxane (18 mL) was stirred at 115 C for 2 h under nitrogen. After dilution with EtOAc (200 mL), the mixture was washed with water and brine. The organic phase was concentrated and the residue was purified by silica gel colunm (petroleum ether: EtOAc , 4:1 to 2:1) to give the compound ten?butyl 4-(4-((4-methoxypyrimidin-2-yl)amino)- 1H-pyrazol- 1 -yl)piperidine- 1 -carboxylate (1.15 g, yield: 48%) as a gray solid. ESI-MS (M+H): 375.2.

1029413-55-5, As the paragraph descriping shows that 1029413-55-5 is playing an increasingly important role.

Reference£º
Patent; BIOGEN IDEC MA INC.; SUNESIS PHARMACEUTICALS, INC.; HOPKINS, Brian, T.; MA, Bin; CHAN, Timothy, Raymond; SUN, Lihong; ZHANG, Lei; KUMARAVEL, Gnanasambandam; LYSSIKATOS, Joseph, P.; KOCH, Kevin; MIAO, Hua; WO2015/89337; (2015); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem